Anti-infection Autophagy Apoptosis Neuronal Signaling Immunology/Inflammation MAPK/ERK Pathway NF-κB Epigenetics Cell Cycle/DNA Damage PI3K/Akt/mTOR Metabolic Enzyme/Protease
Fungal Autophagy Apoptosis PINK1/Parkin NOD-like Receptor (NLR) Caspase JNK NF-κB Sirtuin AMPK Reactive Oxygen Species (ROS)
(+)-Magnoflorine iodide

Cat. No.: HY-N0334A

(+)-Magnoflorine iodide

(Synonyms: Magnoflorine iodide; α-Magnoflorine iodide; Thalictrine iodide)

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

(+)-Magnoflorine (α-Magnoflorine) iodide is an orally active aporphine alkaloid with multiple biological activities. (+)-Magnoflorine iodide promotes Parkin/PINK1 -mediated mitochondrial autophagy, inhibits the activation of NLRP3/Caspase-1 pathway, regulates the intestinal microbiota, and exhibits significant anti-inflammatory and immunomodulatory activities. (+)-Magnoflorine iodide inhibits JNK and TLR4/NF-κB signaling pathways, activates Sirt1/AMPK pathway, alleviates neuronal oxidative stress and apoptosis. Magnoflorine upregulates miR-410-3p, inhibits HMGB1/NF-κB pathway, and has anti-tumor activity. (+)-Magnoflorine iodide also has significant antifungal activity.

For research use only. We do not sell to patients.

Purity: 99.74%
CAS No.: 4277-43-4
Formula: C₂₀H₂₄INO₄
Molecular Weight:469.31

Storage:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

(+)-Magnoflorine iodide Chemical Structure

CAS No.: 4277-43-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All NOD-like Receptor (NLR) Isoforms :

All Caspase Isoforms :

All JNK Isoforms :

All NF-κB Isoforms :

All Sirtuin Isoforms :

All AMPK Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
KB	IC₅₀	>533 μM Compound: magnoflorine iodide	Cytotoxicity against human KB cells after 72 hrs Cytotoxicity against human KB cells after 72 hrs	[PMID: 11141105]

In Vitro

(+)-Magnoflorine iodide has significant antifungal activities against Penicillium avellaneum UC-4376, T. rubrum and T. mentagrophyte with MIC values of 5 μg/disc, 62.5 μg/mL and 62.5 μg/mL, respectively^[1]^[2].
(+)-Magnoflorine (5-80 μM, 24 h) iodide inhibit the proliferation, invasion and epithelial-mesenchymal transition process of MG-63 and U-2 OS cells^[3].
(+)-Magnoflorine (10-40 μM, 24 h) iodide upregulates miR-410-3p and thereby inhibits the HMGB1/NF-κB pathway^[3].
(+)-Magnoflorine (10 μM, 27 h) iodide significantly reverses the decline in PC12 cell viability caused by Aβ1-42and reduces the apoptosis rate^[4].
(+)-Magnoflorine (10 μM, 27 h) iodide significantly reduces the increase in intracellular ROS levels caused by Aβ1-42, and restores the damaged mitochondrial membrane potential^[4].
(+)-Magnoflorine (0-50 μM, 24 h) iodide inhibits the activation of the NLRP3 inflammasome in HK-2 cells by promoting Parkin-dependent mitochondrial autophagy^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Invasion Assay^[3]

Cell Line:

MG-63 and U-2 OS cells
Concentration:

10, 20 and 40 μM
Incubation Time:

24 h
Result:

Significantly reduced the number of MG-63 and U-2 OS cells passing through the matrix gel.

RT-PCR^[3]

Cell Line:

MG-63 and U-2 OS cells
Concentration:

10, 20 and 40 μM
Incubation Time:

24 h
Result:

Upregulated the expression of E-cadherin in a dose-dependent manner, and downregulate the expressions of N-cadherin and Vimentin.
Dose-dependently down-regulates the mRNA expression of HMGB1.
Inhibited the activation of the NF-κB pathway resulting in a decrease in the levels of phosphorylated-p65 and phosphorylated-IκBα.
Significantly upregulated the expression of miR-410-3p in osteosarcoma cells.

Western Blot Analysis^[3]

Cell Line:

MG-63 and U-2 OS cells
Concentration:

10, 20 and 40 μM
Incubation Time:

24 h
Result:

Upregulated the expression of E-cadherin in a dose-dependent manner, and downregulate the expressions of N-cadherin and Vimentin.
Dose-dependently down-regulates the protein expression of HMGB1.
Inhibited the activation of the NF-κB pathway resulting in a decrease in the levels of phosphorylated-p65 and phosphorylated-IκBα.
Significantly upregulated the expression of miR-410-3p in osteosarcoma cells.

Apoptosis Analysis^[4]

Cell Line:

PC12 cells
Concentration:

10 μM
Incubation Time:

pre-treated for 3 h, and then add Aβ1-42 for co-culture for 24 h
Result:

Significantly reduced the apoptosis rate caused by Aβ1-42.
Reduced the expression of pro-apoptotic proteins Bax and Cleaved Caspase-3, and increased the expression of anti-apoptotic protein Bcl-2.

In Vivo

(+)-Magnoflorine (1-10 mg/kg, i.p., once daily for a month) iodide significantly improves the cognitive dysfunction of Alzheimer’s disease (AD) model mice^[4].
(+)-Magnoflorine (10-20 mg/kg, i.g., once daily for 15 days) iodide has a protective effect on cerebral ischemia-reperfusion injury in rats^[5].
(+)-Magnoflorine (10 mg/kg, i.g., once daily for 10 days) iodide relieves colitis induced by DDS (HY-116282C) in mice and the concurrent anxiety-like behaviors^[6].
(+)-Magnoflorine (5-10 mg/kg, i.g., once daily for 12 weeks) iodide exhibits renal protective effects in a mouse model of chronic kidney disease induced by a high-fat and high-fructose diet^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

AD model established in APP/PS1 (APPswe/PSEN1dE9) double-transgenic mice (8 months, 30-32 g, female)^[4]
Dosage:

1 and 10 mg/kg
Administration:

Intraperitoneal injection (i.p.), once daily for a month
Result:

Improved the learning and memory abilities of mice.
Reduced the core pathological changes in the brain, including Aβ deposition, excessive phosphorylation of Tau protein, neuroinflammation and neuronal loss.

Animal Model:

Middle cerebral artery occlusion (MCAO) models model established in male Sprague-Dawley rats (weighing 220 g)^[5]
Dosage:

10 and 20 mg/kg
Administration:

Intragastric administration (i.g.), once daily for 15 days
Result:

Significantly reduced the neurological deficit score, indicating that it improved motor, balance and sensory functions.
Significantly reduced the volume of cerebral infarction and decreased the brain water content.
Reduced the number of damaged neurons shown by Nissl staining and increased the density of NeuN-positive neurons.
Reduced the upregulation of LC3 fluorescence intensity and the LC3-II/LC3-I ratio caused by cerebral ischemia, and increased the expression of p62, Sirt1 and p-AMPK proteins.

Animal Model:

Colitis models model established in female C57BL/6 J mice (6-8 weeks old)^[6]
Dosage:

10 mg/kg
Administration:

Intragastric administration (i.g.), once daily for 10 days
Result:

Reduced the disease activity index, the length of the colon, the tissue pathological damage, and decreased the mRNA levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in the colon tissue.
Significantly improved the anxiety-like behaviors induced by DSS.
Inhibited the activation of microglia (IBA1+) in the hippocampus caused by DSS.
Reduced the mRNA levels of TNF-α, IL-1β, and IL-6 in the hippocampal tissue, and upregulated the expression of tight junction proteins ZO-1 and PV1 in the choroid plexus and blood-brain barrier.
Promoted the production of secondary bile acid HDCA by the microbiota.

Animal Model:

Chronic kidney disease model established in male C57BL/6 J mice (20 g)^[6]
Dosage:

5 and 10 mg/kg
Administration:

Intragastric administration (i.g.), once daily for 12 weeks
Result:

Significantly reduced the levels of serum creatinine, urea nitrogen, uric acid and elevated urine protein.
Reduced the fatty degeneration of renal tubules, lipid deposition and tubular dilation.
Reduced the collagen deposition in the kidneys, and downregulated the mRNA and protein expressions of fibrosis-related markers (TGF-β, α-SMA, COL-I, COL-III).
Reduced the levels of reactive oxygen species (ROS) and malondialdehyde (MDA) in the kidneys, and increased the activity of total superoxide dismutase (T-SOD).
Inhibited the activation of the NLRP3 inflammasome (reduced the expression of NLRP3, ASC, Cleaved Caspase-1, GSDMD-N and IL-1β).

Chemical Information

CAS No. 4277-43-4
Appearance Solid
Molecular Weight 469.31
Formula C₂₀H₂₄INO₄
Color White to light yellow
SMILES

C[N+]1(C)CCC2=CC(OC)=C(O)C3=C2[C@]1([H])CC4=CC=C(OC)C(O)=C34.[I-]
Synonyms

Magnoflorine iodide; α-Magnoflorine iodide; Thalictrine iodide
Structure Classification
- Alkaloids
- Isoquinoline Alkaloids
- Phenols
- Polyphenols
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (1)

All

Sort by:

Journal Impact Factor

SSRN

2025 Jul 10.

Solvent & Solubility

In Vitro:

DMSO : 62.5 mg/mL (133.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1308 mL

10.6539 mL

21.3079 mL

5 mM

0.4262 mL

2.1308 mL

4.2616 mL

10 mM

0.2131 mL

1.0654 mL

2.1308 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 10 mg/mL (21.31 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (294 KB)
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Korean - KR (420 KB)
- Portuguese - PT (420 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Chen JH, et al. Aporphine alkaloids from Clematis parviloba and their antifungal activity. Arch Pharm Res. 2009 Jan;32(1):3-5. [Content Brief]

[2]. Luo N, et al. Antifungal activity and potential mechanism of magnoflorine against Trichophyton rubrum. J Antibiot (Tokyo). 2021 Mar;74(3):206-214. [Content Brief]

[3]. Wang Y, et al. Magnoflorine inhibits the malignant phenotypes and increases cisplatin sensitivity of osteosarcoma cells via regulating miR-410-3p/HMGB1/NF-κB pathway. Life Sci. 2020 Sep 1;256:117967. [Content Brief]

[4]. Zhong L, et al. Magnoflorine improves cognitive deficits and pathology of Alzheimer's disease via inhibiting of JNK signaling pathway. Phytomedicine. 2023 Apr;112:154714. [Content Brief]

[5]. Liang H, et al. Magnoflorine Attenuates Cerebral Ischemia-Induced Neuronal Injury via Autophagy/Sirt1/AMPK Signaling Pathway. Evid Based Complement Alternat Med. 2022 Sep 10;2022:2131561. [Content Brief]

[6]. Wang L, et al. Magnoflorine alleviates colitis-induced anxiety-like behaviors by regulating gut microbiota and microglia-mediated neuroinflammation. Microbiome. 2025 Jul 26;13(1):172. [Content Brief]

[7]. Cheng Y, et al. Magnoflorine Ameliorates Chronic Kidney Disease in High-Fat and High-Fructose-Fed Mice by Promoting Parkin/PINK1-Dependent Mitophagy to Inhibit NLRP3/Caspase-1-Mediated Pyroptosis. J Agric Food Chem. 2024 Jun 5;72(22):12775-12787. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1308 mL	10.6539 mL	21.3079 mL	53.2697 mL
	5 mM	0.4262 mL	2.1308 mL	4.2616 mL	10.6539 mL
	10 mM	0.2131 mL	1.0654 mL	2.1308 mL	5.3270 mL
	15 mM	0.1421 mL	0.7103 mL	1.4205 mL	3.5513 mL
	20 mM	0.1065 mL	0.5327 mL	1.0654 mL	2.6635 mL
	25 mM	0.0852 mL	0.4262 mL	0.8523 mL	2.1308 mL
	30 mM	0.0710 mL	0.3551 mL	0.7103 mL	1.7757 mL
	40 mM	0.0533 mL	0.2663 mL	0.5327 mL	1.3317 mL
	50 mM	0.0426 mL	0.2131 mL	0.4262 mL	1.0654 mL
	60 mM	0.0355 mL	0.1776 mL	0.3551 mL	0.8878 mL
	80 mM	0.0266 mL	0.1332 mL	0.2663 mL	0.6659 mL
	100 mM	0.0213 mL	0.1065 mL	0.2131 mL	0.5327 mL

(+)-Magnoflorine iodide

1 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

(+)-Magnoflorine iodide

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Antifungal Compound Library

Phenols Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Alzheimer's Disease Compound Library

Alkaloids Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Protease Inhibitor Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Inflammasomes related Compound Library

Multi-Target Compound Library

Radioprotector Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Pattern Recognition Receptors Library